Lower mGPS, and better ECOG PS were associated with longer continuation of anamorelin, whereas patients with gastric cancer showed a tendency toward shorter duration. These findings provide guidance for patient selection and tailored supportive care in clinical practice.
Kanbayashi et al. (Mon,) studied this question.